TFEB and Parkinson disease: Finally, our results position genistein as an interesting FDA-approved drug for the treatment of diseases in which lysosomes and TFEB have been proposed as therapeutic targets, such as the LSDs NPC, Batten, Gaucher, MPS, and Pompe disease, among others [36,57] as well as diseases with lysosomal dysfunction and neurological compromises, such as Alzheimer’s and Parkinson’s [61].